Parameter
| Biomarker | Truncated STMN2 | Full name | Truncated Stathmin-2 (STMN2) | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Pathological Confirmation, Diagnosis |
| Disease | Amyotrophic Lateral Sclerosis | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | CSF (Western Blot, IP-MS) | ||
| Pathobiological Mechanisms | TDP-43 aggregation inhibits normal splicing of STMN2, producing truncated proteins that interfere with microtubule function. | ||||
| Clinical Availability Status | Research exploration stage | ||||
| Notes and Dynamics | Truncated STMN2 can be detected in CSF of 90% of ALS patients, positively correlated with TDP-43 aggregation; a potential efficacy biomarker for TDP-43 targeted therapy. | ||||